drugset / Trial / NCT07184918

Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography

NCT07184918

Completed 44 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial evaluates whether continuing or withholding ACE inhibitors (specifically Ramipril) before coronary angiography affects the risk of contrast-induced nephropathy (CIN). CIN is a known complication of iodinated contrast exposure, particularly in patients with chronic conditions such as hypertension or diabetes. The trial involves 44 adult patients randomized into two groups: one continuing Ramipril and the other withholding it 48 hours before and restarting 72 hours after the procedure. Renal biomarkers including serum creatinine, NGAL, and superoxide dismutase will be assessed to evaluate renal function.

Timeline

Start
2024-02-01
Primary completion
2025-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramipril Small molecule

Indications